<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232022</url>
  </required_header>
  <id_info>
    <org_study_id>14-336</org_study_id>
    <nct_id>NCT02232022</nct_id>
  </id_info>
  <brief_title>Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke</brief_title>
  <official_title>Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the incidence of paroxysmal atrial fibrillation&#xD;
      (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial&#xD;
      fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies suggest that their is a relatively high incidence of silent paroxysmal atrial&#xD;
      fibrillation (PAF) in cryptogenic ischemic stroke patients. Detection of silent PAF in this&#xD;
      population, however, requires prolonged cardiac monitoring. On the other hand, there is no&#xD;
      understanding of the frequency of silent PAF in patients with a &quot;known&quot; or presumed etiology&#xD;
      for their ischemic stroke other than AF. If this incidence is also found to be significant, a&#xD;
      dramatic change in stroke evaluation and management would likely occur. This study intends to&#xD;
      find the incidence of PAF in a population of recent (within 7 days) ischemic stroke patients&#xD;
      (or MRI positive &quot;transient ischemic attack (TIA)&quot; patients) who have presumed etiology for&#xD;
      their stroke other than atrial fibrillation or other high risk cardiac lesion. Stroke&#xD;
      etiology will be determined through a standard post-stroke evaluation that includes:&#xD;
&#xD;
        -  Brain MRI&#xD;
&#xD;
        -  12-lead electrocardiogram (ECG) for AF detection&#xD;
&#xD;
        -  24-h ECG monitoring for AF detection (eg, Holter monitor or cardiac telemetry)&#xD;
&#xD;
        -  Transthoracic and/or Transesophageal echocardiogram&#xD;
&#xD;
        -  CT or MR angiography of the head and neck&#xD;
&#xD;
        -  Hypercoagulable blood panel for patients less than 55 years-old. Preliminary&#xD;
           hypercoagulable work-up within 7 days will include the antiphospholipid antibody&#xD;
           syndrome results, which will be needed to determine stroke management. All other&#xD;
           results, which could take longer to return, including genetic tests of&#xD;
           hypercoagulability, rarely change stroke management.&#xD;
&#xD;
      To find occult PAF in this population, participants will have an insertable cardiac monitor&#xD;
      (Reveal LINQ ICM) implanted within 7 days of the incident stroke and will be monitored for at&#xD;
      least 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2014</start_date>
  <completion_date type="Actual">September 28, 2017</completion_date>
  <primary_completion_date type="Actual">September 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Who Are Diagnosed With AF Who Are Changed to Anticoagulant Therapy.</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients who are diagnosed with AF who are changed to anticoagulant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of AF Episodes.</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of AF episodes (mean and range).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Asymptomatic AF</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of asymptomatic AF episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Recurrent Stroke</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of recurrent ischemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Had Multiple AF Episodes</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients that had multiple AF episodes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>NonCryptogenic Ischemic Stroke Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-cryptogenic ischemic stroke will be enrolled within 10 days of stroke onset</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reveal LINQ Insertable Cardiac Monitor</intervention_name>
    <arm_group_label>NonCryptogenic Ischemic Stroke Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a recent ischemic stroke or transient ischemic attack (TIA) with brain&#xD;
             infarction on brain imaging.&#xD;
&#xD;
          -  No history of atrial fibrillation or finding of atrial fibrillation on standard&#xD;
             inpatient monitoring (electrocardiogram, telemetry, 24-hour Holter monitor)&#xD;
&#xD;
          -  Have a presumed stroke etiology: Lacunar or small vessel thrombosis, extra-cranial or&#xD;
             intracranial atherosclerotic stenosis or dissection, arteriopathy or vasculitis,&#xD;
             hypercoagulable state, aortic arch plaque with or without mobile elements, or evidence&#xD;
             of a low-risk cardiac source (e.g., patent foramen ovale with or without atrial septal&#xD;
             aneurysm and with or without evidence of venous thromboembolic source).&#xD;
&#xD;
          -  Have virtual CHADS2 score ≥3 or&#xD;
&#xD;
          -  Have 2 or more of the following co-morbidities: obstructive sleep apnea, coronary&#xD;
             artery disease, (Chronic Pulmonary Obstructive Disease (COPD), hyperthyroidism, Body&#xD;
             Mass Index&gt; 30, prior myocardial infarction, prolonged PR interval (&gt;175 ms) or renal&#xD;
             impairment (GFR 30-60).&#xD;
&#xD;
          -  Patient or legally authorized representative who is willing to sign written consent&#xD;
             form.&#xD;
&#xD;
          -  Patient is ≥40 years old (patients younger than 40 years old have a very low&#xD;
             likelihood of having atrial fibrillation and are therefore excluded from the study).&#xD;
&#xD;
          -  Patient can have the device implanted within 7 days of the incident ischemic event&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of AF or atrial flutter.&#xD;
&#xD;
          -  Evidence of a high-risk cardiac source of embolism (Left Ventricular or Left Atrial&#xD;
             thrombus or &quot;smoke,&quot; emboligenic valvular lesion or tumor)&#xD;
&#xD;
          -  Untreated hyperthyroidism.&#xD;
&#xD;
          -  Myocardial infarction or coronary bypass grafting within 1 month prior to the&#xD;
             stroke/TIA.&#xD;
&#xD;
          -  Valvular disease requiring immediate surgical intervention.&#xD;
&#xD;
          -  Permanent indication for anticoagulation at enrollment.&#xD;
&#xD;
          -  Permanent oral anticoagulation contraindication.&#xD;
&#xD;
          -  Already included in another clinical trial that will affect the objectives of this&#xD;
             study.&#xD;
&#xD;
          -  Life expectancy is less than 1 year.&#xD;
&#xD;
          -  Pregnancy. Urine or serum pregnancy test is required for women of child bearing&#xD;
             potential to exclude pregnancy.&#xD;
&#xD;
          -  Patient is indicated for implant with a pacemaker, implantable&#xD;
             cardioverter-defibrillator, CRT device, or an implantable hemodynamic monitoring&#xD;
             system&#xD;
&#xD;
          -  Patient is not fit, or is unable or unwilling to follow the required procedures of the&#xD;
             Clinical Investigation Plan.&#xD;
&#xD;
          -  Cryptogenic Stroke: A stroke/TIA will be considered cryptogenic if no cause is&#xD;
             determined despite extensive inpatient workup according to the standard diagnostic&#xD;
             protocol at North Shore University Hospital.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey M. Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2014</study_first_posted>
  <results_first_submitted>March 11, 2019</results_first_submitted>
  <results_first_submitted_qc>June 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2019</results_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Jeffrey Katz</investigator_full_name>
    <investigator_title>Chief, Vascular Neurology</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Ischemic stroke</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Insertable cardiac monitor</keyword>
  <keyword>Non-cryptogenic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 16, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02232022/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NonCryptogenic Ischemic Stroke Patients</title>
          <description>In this pilot prospective cohort study of non-CIS patients from September 2014 to September 2017. Patients were implanted within 10 days of stroke onset with the Reveal LINQ insertable cardiac monitor and monitored until PAF detection or a minimum of 12 months. Inclusion required diagnosis of a non-AF stroke etiology, age≥40, and either a virtual CHADS2 score ≥3 or ≥2 PAF related comorbidities.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NonCryptogenic Ischemic Stroke Patients</title>
          <description>In this pilot prospective cohort study of non-CIS patients from September 2014 to September 2017, 53 patients were enrolled. 51/53 patients were implanted within 10 days of stroke onset with the Reveal LINQ insertable cardiac monitor and monitored until PAF detection or a minimum of 12 months.&#xD;
Inclusion required diagnosis of a non-AF stroke etiology, age≥40, and either a virtual CHADS2 score ≥3 or ≥2 PAF related comorbidities.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline AF Assessment</title>
          <description>Baseline AF Assessment completed using 24 hour ECG monitoring</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients</title>
        <description>The incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NonCryptogenic Ischemic Stroke</title>
            <description>Reveal LINQ Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients</title>
          <description>The incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Are Diagnosed With AF Who Are Changed to Anticoagulant Therapy.</title>
        <description>Percentage of patients who are diagnosed with AF who are changed to anticoagulant therapy.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NonCryptogenic Ischemic Stroke Patients</title>
            <description>In this pilot prospective cohort study of non-CIS patients from September 2014 to September 2017, 53 patients were enrolled. 51/53 patients were implanted within 10 days of stroke onset with the Reveal LINQ insertable cardiac monitor and monitored until PAF detection or a minimum of 12 months. Inclusion required diagnosis of a non-AF stroke etiology, age≥40, and either a virtual CHADS2 score ≥3 or ≥2 PAF related comorbidities.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Are Diagnosed With AF Who Are Changed to Anticoagulant Therapy.</title>
          <description>Percentage of patients who are diagnosed with AF who are changed to anticoagulant therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of AF Episodes.</title>
        <description>Duration of AF episodes (mean and range).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NonCryptogenic Ischemic Stroke Patients</title>
            <description>In this pilot prospective cohort study of non-CIS patients from September 2014 to September 2017, 53 patients were enrolled. 51/53 patients were implanted within 10 days of stroke onset with the Reveal LINQ insertable cardiac monitor and monitored until PAF detection or a minimum of 12 months. Inclusion required diagnosis of a non-AF stroke etiology, age≥40, and either a virtual CHADS2 score ≥3 or ≥2 PAF related comorbidities.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of AF Episodes.</title>
          <description>Duration of AF episodes (mean and range).</description>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237" lower_limit="1" upper_limit="1122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Asymptomatic AF</title>
        <description>Percentage of asymptomatic AF episodes.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NonCryptogenic Ischemic Stroke Patients</title>
            <description>Reveal LINQ Insertable Cardiac Monitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Asymptomatic AF</title>
          <description>Percentage of asymptomatic AF episodes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Recurrent Stroke</title>
        <description>Incidence of recurrent ischemic stroke.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NonCryptogenic Ischemic Stroke Patients</title>
            <description>Reveal LINQ Insertable Cardiac Monitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Recurrent Stroke</title>
          <description>Incidence of recurrent ischemic stroke.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Had Multiple AF Episodes</title>
        <description>Number of patients that had multiple AF episodes.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NonCryptogenic Ischemic Stroke</title>
            <description>Reveal LINQ Insertable Cardiac Monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Had Multiple AF Episodes</title>
          <description>Number of patients that had multiple AF episodes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NonCryptogenic Ischemic Stroke Patients</title>
          <description>Reveal LINQ Insertable Cardiac Monitor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Device Erosion</sub_title>
                <description>1 patient had a complication of impending device erosion through the skin. Managed with antibiotics and device removal.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively small sample size limits our study's power to detect and confirm all factors associated with PAF detection. The number of non-PAF patients lost to follow-up by 6 and 12 months that may have resulted in an underestimation of PAF burden.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey M. Katz</name_or_title>
      <organization>Northwell Health</organization>
      <phone>516-562-3062</phone>
      <email>jkatz2@northwell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

